# Adversarial re-verification verdict - hereditary_papillary_renal_carcinoma.md

## 1. DOSE LEAK
None. Grepped for `[0-9]+ ?mg`, `mg/m2`, `AUC ?[0-9]`, `q[0-9]+[wd]`, `every N days/weeks`, cycle/day
tokens - zero hits. All numerals present are non-dose descriptive stats matching DeVita: "fewer than
35 kindreds" (DeVita: "less than 35 kindreds worldwide"), "near-complete penetrance by age 80"
(DeVita: "nearly complete penetrance by 80 years of age"), trisomy of "chromosome 7", ">90%"
cancer-specific survival for T1 (DeVita: >98% T1a/90% T1b/86% T2), "30%" renal-remnant threshold
(DeVita: "at least 30% of a well-functioning remnant kidney"), thermal-ablation "<3 cm" cutoff
(DeVita: same), "12th ed." (edition number). No drug doses, no AUC, no schedule numbers anywhere.

## 2. UNGROUNDED / MISLABELLED CLAIMS
None found. The single blocking finding from the prior verdict (the false claim that DeVita's
HPRC section "does not name or validate a specific agent" / "does not lay out a disease-specific
systemic-therapy algorithm") has been corrected throughout the file. Spot-checked every specific
claim against devita.txt:
- Foretinib phase II trial in bilateral/multifocal/metastatic papillary RCC and HPRC with germline
  MET mutation, activity in advanced papillary RCC with highest response in germline-MET patients -
  confirmed verbatim (lines ~149988-149996). Sidecar now correctly states DeVita reports this
  HPRC-specific data point, omits DeVita's ORR 13.5%/PFS 9.3-month figures (not required, no dose
  leak either way), and correctly notes no dose/schedule is given for foretinib in DeVita.
- "Multifocal or familial RCC" as an indication favoring partial over radical nephrectomy -
  confirmed (line ~150487).
- "At least 30% of a well-functioning remnant kidney" avoiding permanent dialysis - confirmed
  verbatim (line ~150505).
- Pre-surgical TKI downstaging enabling nephron-sparing surgery - confirmed (lines ~150507-509).
- Thermal ablation <3cm, higher local recurrence (10-20%) vs PN/RN, Mayo series comparable cT1a
  outcomes to PN - confirmed (lines ~150547-150610).
- Lymphadenectomy limited/controversial benefit outside high-risk/node-positive - confirmed
  (lines ~150390-150396).
- SBRT as palliative-only option for unresectable disease with major IVC/venous involvement -
  confirmed (lines ~150838-150845).
- Everolimus efficacy maintained across histologies, first-line use not trial-supported, pushed to
  third-line behind cabozantinib/nivolumab - confirmed near-verbatim (line ~28031).
- Adjuvant trial roster ASSURE, SORCE, ATLAS, PROTECT, ARISER - all five confirmed as named trials
  in DeVita's Table 43.7 (~151106-151244) / text (~150865-150920).
- Adjuvant pembrolizumab vs placebo post-nephrectomy phase III trial improving RFS - confirmed
  (line ~32972-32976), correctly flagged as clear-cell-centered evidence not established for
  HPRC/papillary histology.
- General-oncology-standard-labelled claims (surveillance-and-treat size-threshold strategy, MET
  mechanistic rationale, NCCN-guided systemic-agent choice) remain correctly labelled "(general
  oncology standard, not from DeVita's section on this disease)" and are not attributed to DeVita.
No claim remains mis-attributed to DeVita; no ungrounded specific regimen/statistic lacks a label.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th
ed. NCCN Guidelines where noted as general oncology standard." Name only, no page numbers.

No em-dashes found (grepped "—", zero hits).

## 4. VERDICT: CLEAN - ready for R1 re-review.
The prior blocking finding (mischaracterizing DeVita as silent on HPRC-specific systemic therapy)
is fixed accurately and consistently across all five locations the reviser identified (Overview,
Advanced-disease section, Lines-of-therapy, Role-of-surgery/systemic-therapy section, Deliberately
omitted). No new dose leak, fabrication, or mis-attribution was introduced in the rewrite.
